Floatz logo

Cabozantinib

Ovarian Carcinoma

M.D. Anderson Cancer CenterSmall moleculePhase 2Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

235 Active assets in the Ovarian Carcinoma cohort.

Asset / SponsorPhaseRating
Trabectedin
AGO Research GmbH
Phase 4BBB
Mirvetuximab Soravtansine
AstraZeneca
Phase 3BBB
Carboplatin
University of Washington
Phase 3BB
Irinotecan
OHSU Knight Cancer Institute
Phase 2BB
Olaparib
Imunon
Phase 4BB

View all 50 →

Same molecule, other indications

Cabozantinib is also rated in:

renal carcinomaActive
BB
Indicative · Phase 4
70 / 100
View asset →
castration-resistant prostate carcinomaActive
BB
Indicative · Phase 3
70 / 100
View asset →
kidney cancerActive
BB
Indicative · Phase 4
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →